US Krystexxa launch in motion, as Savient touts gout drug for "an unmet medical need", but concedes ramp-up may be slow
This article was originally published in Scrip
Executive Summary
Savient Pharmaceuticals has faced a few obstacles in bringing Krystexxa (pegloticase) to US specialists, but the company says that a formal launch is now underway - with the injectable product positioned as the first and only therapy available to treat chronic gout in adults refractory to conventional therapy. Uncertainty remains, however, on whether the small biotech can execute an effective marketing plan, and whether anyone has a handle on all of the unknowns about the true eligible population.